glp-1 molecular structure Glucagon-Like Peptide 1 - an overview Human GLP-1 receptor transmembrane domain

Diabetes Care 39 , 23042310 (2016)

As Hemmi notes: Some people will lose access. In an emailed statement to WIRED, a spokesperson for Novo Nordisk says, Moving forward, any compounder that mass produces or sells knockoff drugs is breaking the law and compromising patient safety. A spokesperson for Eli Lilly echoed that sentiment, saying via email that the FDA and a federal court have both made clear that compounders must cease production of compounded tirzepatide knockoffs. Anthony Comuzzie, CEO of the Obesity Society, recognizes that there are legitimate access issues to GLP-1 medications, but he worries that some people who have sought out compounded versions may not meet the medical definition of obesity and are using them more casually for weight loss

Recent trials show that overweight or obese patients saw a 14.9% reduction in body weight after taking once-weekly semaglutide 2.4 mg for 68 weeks, compared to a 2.4% reduction in body weight for the control [24]

In other words, you can start reaching your goals without the hassle of fitting in a doctors appointment or making it to the pharmacy before it closes